Fischer synthesis of isomeric thienopyrrole LHRH antagonists

Tetrahedron

Volumn 65, Issue 29-30, 2009, Pages 5805-5816

  Andrews, David M ^a   Arnould, Jean Claude ^a   Boutron, Pascal ^a   Délouvrie, Bénédicte ^a   Delvare, Christian ^a   Foote, Kevin M ^a   Hamon, Annie ^a   Harris, Craig S ^a   Lambert van der Brempt, Christine ^a   Lamorlette, Maryannick ^a   Matusiak, Zbegniew M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Fischer; LHRH anatagonists; Thienopyrrole

Indexed keywords

2 [2 (7 AZABICYCLO[2.2.1]HEPT 7 YL) 1,1 DIMETHYL 2 OXOETHYL] 5 (3,5 DIMETHYLPHENYL) 4 [2 [4 (2 OXO 2 PYRROLIDIN 1 YLETHYL)PIPERAZIN 1 YL]ETHYL] 6H THIENO[2,3 B]PYRROLE; 2 [2 (7 AZABICYCLO[2.2.1]HEPT 7 YL) 1,1 DIMETHYL 2 OXOETHYL] 5 (3,5 DIMETHYLPHENYL) 6 [2 [4 (2 OXO 2 PYRROLIDIN 1 YLETHYL)PIPERAZIN 1 YL]ETHYL] 4H THIENO[3,2 B]PYRROLE; 3 [2 (7 AZABICYCLO[2.2.1]HEPT 7 YL) 1,1 DIMETHYL 2 OXOETHYL] 5 (3,5 DIMETHYLPHENYL) 4 [2 [4 (2 OXO 2 PYRROLIDIN 1 YLETHYL)PIPERAZIN 1 YL]ETHYL] 6H THIENO[2,3 B]PYRROLE; 4 [2 (7 AZABICYCLO[2.2.1]HEPT 7 YL) 1,1 DIMETHYL 2 OXOETHYL] 2 (3,5 DIMETHYLPHENYL) 3 [2 [4 (2 OXO 2 PYRROLIDIN 1 YLETHYL)PIPERAZIN 1 YL]ETHYL] 1H THIENO[3,4 B]PYRROLE; 7 [4 [5 (3,5 DIMETHYLPHENYL) 4 [2 [4 (2 OXO 2 PYRROLIDIN 1 YLETHYL)PIPERAZIN 1 YL]ETHYL] 1H PYRROL 3 YL] 2,2 DIMETHYLBUTANOYL] 7 AZABICYCLO[2.2.1]HEPTANE; GONADORELIN ANTAGONIST; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 67249116489     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2009.05.007     Document Type: Article

References (38)

1. Furr B.J.A., and Woodburn J.R. J. Endocrinol. Invest. 11 (1988) 535-557
2. Schally A.V. Peptides 20 (1999) 1247-1262
3. Debruyne F.M. Rev. Urol. 6 (2004) 25-32
4. Huirine J.A.F., and Lambalk C.B. Lancet 358 (2001) 1793-1803
5. Persson, B. E.; Jensen, J. K.; Olesen, T. K. 9th Int. Symp. GnRH 2008, Berlin;
6. Boccon-Gibod, L.; Klotz, L.; Schroeder, H.; Andreou, C.; Persson, B. E.; Cantor, P.; Jensen, J. K.; Kold Olesen, T. Eur. Urol. Suppl. 2008, 7, Abstract 537.
7. Regan C.F., Guo Z., Chen Y., Huang C.Q., Chen M., Jiang W., Rueter J.K., Coon T., Chen C., Saunders J., Brown M.S., Betz S.F., Struthers R.S., Yang C., Wen J., Madan A., and Zhu Y.-F. Bioorg. Med. Chem. Lett. 18 (2008) 4503-4507 (and references cited therein)
8. Luthin D.R., Hong Y., Tompkins E., Anderes K.L., Paderes G., Kraynov E.A., Castro M.A., Nared-Hood K.D., Castillo R., Gregory M., Vazir H., May J.M., and Anderson M.B. Bioorg. Med. Chem. Lett. 12 (2002) 3635-3639
9. Young J.R., Huang S.X., Walsh T.F., Wyvratt M.J., Yang Y.T., Yudkovitz J.B., Cui J., Mount G.R., Ren R.N., Wu T.-J., Shen X., Lyons K.A., Mao A.-H., Carlin J.R., Karanam B.V., Vincent S.H., Cheng K., and Goulet M.T. Bioorg. Med. Chem. Lett. 12 (2002) 827-832 (and references cited therein)
10. Sasaki S., Cho N., Nara Y., Harada M., Endo S., Suzuki N., Furuya S., and Fujino M. J. Med. Chem. 46 (2003) 113-124 (and references cited therein)
11. Arnould J.-C., Delouvrie B., Boutron P., Dossetter A.G., Foote K.M., Hamon A., Hancox U., Harris C.S., Hutton M., Lamorlette M., and Matusiak Z. Bioorg. Med. Chem. Lett. 17 (2007) 6448-6454
12. Blair J.B., Marona-Lewicka D., and Kanthasamy A. J. Med. Chem. 42 (1999) 1106-1111
13. Ontoria J.M., Marti{dotless}n Hernando J.M., Malancona S., Attenni B., Stansfield I., Conte I., Ercolani C., Habermann J., Ponzi S., Di Filippo M., Koch U., Rowley M., and Narjes F. Bioorg. Med. Chem. Lett. 16 (2006) 4026-4030
14. Fischer E., and Jourdan F. Ber. 16 (1883) 2241
15. Fischer E., and Hess O. Ber. 17 (1884) 559
16. Larock R.C., and Yum E.K. J. Am. Chem. Soc. 113 (1991) 6689-6690
17. Larock R.C., and Zenner J.M. J. Org. Chem. 60 (1995) 482-483
18. Malacona S., Martin Hernando J.L., Atteni B., Ontoria J.M., and Narjes F. Tetrahedron Lett. 50 (2009) 1625-1628
19. Garcia F., and Glàvez C. Synthesis (1985) 143-156
20. Binder D., Habison G., and Noe C.R. Synthesis 7 (1977) 487-489
21. Tamura Y., Minamikawa J., Sumuto K., Fujii S., and Ikeda M. J. Org. Chem. 68 (1973) 1239-1241
22. Colvin E.W., Kirby G.W., and Wilson A.C. Tetrahedron Lett. 23 (1982) 3835-3836
23. DSC testing gave the following results:
24. O-(4-Nitrobenzoyl)-hydroxylamine; large exotherm from 78 °C, which was complete at 200 °C (heat of decomposition 821 J/g). Second large exotherm from 249 °C, which was complete at 393 °C (heat of decomposition 1120 J/g);
25. O-(2,4-Dinitrophenyl)hydroxylamine; sharp endotherm seen from 103 °C which ran immediately into a large exotherm from 112 °C. The exotherm was complete at 176 °C (heat of decomposition 961 J/g). Second large exotherm from 211 °C, which was complete at 380 °C (heat of decomposition 2548 J/g);
26. O-(Diphenylphosphinyl)hydroxylamine; large, sharp exotherm from 94 °C. Exotherm complete at 140 °C, heat of decomposition 702 J/g. Heats of decomposition of >800 J/g generally indicates possible explosive properties (Recommendations for the Transport of Dangerous Goods Manual on Tests and Criteria 2003, 4th Edition, United Nations, Economic Commission for Europe); for a recent reference evaluating the stability of the mesitylene version see. Mendiola J., Rincon J.A., Mateos C., Francisco Soriano J., de Frutos O., Niemeier J.K., and Davis E.M. Org. Proc. Res. Dev. 13 (2009) 263-267
27. Robinson B. Chem. Rev. 4 (1963) 373-401
28. Cheng J., and Trudell M.L. Org. Lett. 3 (2001) 1371-1374
29. Harris, C. S. PCT Int. Appl. 2005, WO2005079805.
30. - on N-{[(chlorosulfinyl)oxy]methylene}-N-methylmethanaminium chloride formed during the first step.
31. Gronowitz S., and Raznikiewicz T. Org. Synth. Collect Vol. V, p 149 (1973) and references cited therein
32. Ertas E., and Ozturk T. Tetrahedron Lett. 45 (2004) 3405-3407
33. Stone K.J., Greenberg M.M., Blackstock S.C., and Berson J.A. J. Am. Chem. Soc. 111 (1989) 3659-3671
34. Khanh L.P., Dallemagne P., Alsaidi A., and Rault S. Heterocycles 45 (1997) 527-535
35. Gronowitz S. Heterocyclic Compounds: Thiophene and its Derivatives Part I (1985), John Wiley and Sons, New York, NY pp 482-554 and references cited therein
36. 6 GnRH to receptors by 50%.
37. 50 value representing the antagonist concentration required to inhibit the GnRH-stimulated LHR release by 50%.
38. Moore J.S., and Stupp S.I. Macromolecules 23 (1990) 65-70